Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
- 1 November 1998
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 352 (9140) , 1586-1589
- https://doi.org/10.1016/s0140-6736(98)02197-7
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteineBritish Journal of Dermatology, 1997
- Thalidomide as an Anti-TNF-α Inhibitor: Implications for Clinical UseClinical Immunology and Immunopathology, 1996
- Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysisBritish Journal of Dermatology, 1996
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Efficacy of cyclophosphamide in toxic epidermal necrolysisJournal of the American Academy of Dermatology, 1991
- Toxic Epidermal NecrolysisArchives of Dermatology, 1987
- Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without CorticosteroidsAnnals of Surgery, 1986
- Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis: Report of a patient treated with corticosteroid “pulse therapy”Journal of the American Academy of Dermatology, 1985
- Burn Rounds:Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Pathophysiologic Review with Recommendations for a Treatment ProtocolJournal of Burn Care & Rehabilitation, 1983